RareResearch.AI
← Back to atlas

V803M

Category 3/4 — Most DruggableUncertain significanceLumenal · predictedσ-1 candidateSource card
ValineMethionine at position 803 · C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type V803 — hydrogen bond to F840
Fullscreen ↗
DynaMut2 mutant · V803M
Mutant M803 — carbonyl to V839 lost (2 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

2 lost2 gained12 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondI777I777Preserved
Hydrogen bondP838P838Preserved
Hydrogen bondV839V839Preserved
Hydrogen bondF840F840Preserved
Polar contactI777I777Preserved
Polar contactP838P838Preserved
Polar contactV839V839Preserved
Polar contactF840F840Preserved
CarbonylI777I777Preserved
CarbonylV839Lost
Van der WaalsI777Gained
Van der WaalsP838P838Preserved
Van der WaalsV839V839Preserved
HydrophobicE776Lost
HydrophobicW837Gained
HydrophobicV839V839Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.36kcal/mol
Destabilising — mild
AlphaMissense
0.727
likely pathogenic
AlphaFold pLDDT
90
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsAutosomal dominant nonsyndromic hearing loss 6; Cataract 41; Wolfram-like syndrome; Type 2 diabetes mellitus; Wolfram syndrome 1
Population frequency (gnomAD v4)Ultra-rare · AF 0.0023%
cDNA changec.2407G>A
ClinVar accessionVCV000229643
Last evaluated2025/07/22 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — V803M Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Valine → Methionine at position 803. C-terminal ER-lumenal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.727, DynaMut2 ΔΔG -0.36 kcal/mol (destabilising).


Identity

FieldValue
VariantV803M (p.Valine803Methionine)
DNA changec.2407G>A
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV000229643
Amino acid changeValine (V) → Methionine (M)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 80390.31 — well-folded
DomainC-terminal ER-lumenal (calcium binding, calmodulin, chaperone)
Position contextC-terminal lumenal domain · position 803 projects into the ER lumen
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 803 sits in the C-terminal lumenal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na+/K+ ATPase β1. The wild-type residue is small hydrophobic (valine — branched); the mutant is hydrophobic sulfur (methionine). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.7272
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.36 (Destabilising)
Job ID178092151914
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092151914

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2025/07/22 00:00
InheritanceAutosomal dominant pattern indicated by associated DFNA6/14/38 (WFS1 hearing loss 6).
WFS1 variant landscapeV803M is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Autosomal dominant nonsyndromic hearing loss 6
  • Cataract 41
  • Wolfram-like syndrome
  • Type 2 diabetes mellitus
  • Wolfram syndrome 1

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.36 < 2 kcal/mol (fold intact) + AlphaMissense 0.727 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.36 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.727. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • V803M_molstar_viewer.html — interactive 3D viewer (auto-highlights position 803 with ball-and-stick + neighbors within 5Å)
  • V803M_variant_card.md — this card (source of truth)
  • V803M_variant_card.html — styled printable card
  • V803M_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • V803M_wildtype_interactions.pse / V803M_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the V803M PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download V803M PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.